首页> 外文期刊>Pediatric blood & cancer >Treatment of refractory hemorrhage with factor XIII in a patient with hemophilia A with inhibitor
【24h】

Treatment of refractory hemorrhage with factor XIII in a patient with hemophilia A with inhibitor

机译:抑制剂治疗甲型血友病患者难治性XIII因子出血

获取原文
获取原文并翻译 | 示例
           

摘要

An 11-year-old male with hemophilia A and a known high-titer Factor VIII inhibitor was admitted with retroperitoneal hemorrhage. The patient was receiving infusions of recombinant activated Factor VII (rFVIIa) for a recent elbow hemorrhage when retroperitoneal bleeding commenced. Despite increased dosing of rFVIIa and a dose of activated prothrombin complex concentrate (aPCC), he continued to hemorrhage and required several blood transfusions. Factor XIII was administered 1hour after rFVIIa and the patient demonstrated cessation of bleeding and normalization of clot strength. Factor XIII may act as an adjuvant in effective clot stabilization in patients with hemophilia and inhibitory antibodies.
机译:一名患有血友病A和已知的高滴度VIII因子抑制剂的11岁男性因腹膜后出血入院。当腹膜后出血开始时,该患者正在接受重组活化因子VII(rFVIIa)的输注,用于近期的肘部出血。尽管增加了rFVIIa的剂量和一定剂量的活化凝血酶原复合物浓缩物(aPCC),他仍继续出血并需要输血几次。 XIII因子在rFVIIa后1小时给药,患者表现出止血和血凝强度恢复正常。 XIII因子可在血友病和抑制性抗体患者中起到有效凝块稳定的佐剂作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号